Renalytix plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Renalytix plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $2.29M | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $3.40M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $2.97M | Sep 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $100.0K | Sep 28, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $156.0K | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $720.0K | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $874.0K | Sep 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | ($33.46M) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | ($45.61M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($45.28M) | Sep 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | ($29.61M) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | ($42.22M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($53.18M) | Sep 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | ($30.11M) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | ($34.09M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($45.92M) | Sep 28, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Jun 30, 2023 | $0 | Sep 28, 2023 |
| FY2023 | Jun 30, 2022 | $557.0K | Sep 28, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $7.97M | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $30.63M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $50.07M | Sep 28, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $15.83M | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $23.66M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $19.46M | Sep 28, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | ($7.85M) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $6.97M | Sep 30, 2024 |
| FY2024 | Jun 30, 2022 | $30.61M | Sep 30, 2024 |
| FY2023 | Jun 30, 2021 | $71.46M | Sep 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | ($211.78M) | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | ($178.33M) | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | ($132.72M) | Sep 28, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $4.68M | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | $24.68M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | $41.33M | Sep 28, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | 0 | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | 0 | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | 0 | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | 154.37M | Sep 30, 2024 |
| FY2024 | Jun 30, 2023 | 93.78M | Sep 30, 2024 |
| FY2023 | Jun 30, 2022 | 74.76M | Sep 28, 2023 |